GB202003668D0 - GPR52 Modulator compounds - Google Patents

GPR52 Modulator compounds

Info

Publication number
GB202003668D0
GB202003668D0 GBGB2003668.7A GB202003668A GB202003668D0 GB 202003668 D0 GB202003668 D0 GB 202003668D0 GB 202003668 A GB202003668 A GB 202003668A GB 202003668 D0 GB202003668 D0 GB 202003668D0
Authority
GB
United Kingdom
Prior art keywords
gpr52
modulator compounds
modulator
compounds
gpr52 modulator
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2003668.7A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nxera Pharma UK Ltd
Original Assignee
Heptares Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heptares Therapeutics Ltd filed Critical Heptares Therapeutics Ltd
Priority to GBGB2003668.7A priority Critical patent/GB202003668D0/en
Publication of GB202003668D0 publication Critical patent/GB202003668D0/en
Priority to HRP20241375TT priority patent/HRP20241375T1/hr
Priority to MX2022011333A priority patent/MX2022011333A/es
Priority to SM20240402T priority patent/SMT202400402T1/it
Priority to CA3175429A priority patent/CA3175429A1/en
Priority to LTEPPCT/GB2021/050638T priority patent/LT4117784T/lt
Priority to ES21713103T priority patent/ES2992600T3/es
Priority to HUE21713103A priority patent/HUE068758T2/hu
Priority to PL21713103.6T priority patent/PL4117784T3/pl
Priority to CN202180033813.9A priority patent/CN115515681B/zh
Priority to KR1020227035100A priority patent/KR20220152296A/ko
Priority to AU2021235257A priority patent/AU2021235257B2/en
Priority to JP2022555137A priority patent/JP7492597B2/ja
Priority to IL296413A priority patent/IL296413B2/en
Priority to FIEP21713103.6T priority patent/FI4117784T3/fi
Priority to US17/909,792 priority patent/US12655120B2/en
Priority to DK21713103.6T priority patent/DK4117784T3/da
Priority to RS20241089A priority patent/RS66063B1/sr
Priority to SI202130212T priority patent/SI4117784T1/sl
Priority to PCT/GB2021/050638 priority patent/WO2021181122A1/en
Priority to EP21713103.6A priority patent/EP4117784B1/en
Priority to PT217131036T priority patent/PT4117784T/pt
Priority to BR112022018287A priority patent/BR112022018287A2/pt
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Amplifiers (AREA)
  • Optical Modulation, Optical Deflection, Nonlinear Optics, Optical Demodulation, Optical Logic Elements (AREA)
GBGB2003668.7A 2020-03-13 2020-03-13 GPR52 Modulator compounds Ceased GB202003668D0 (en)

Priority Applications (23)

Application Number Priority Date Filing Date Title
GBGB2003668.7A GB202003668D0 (en) 2020-03-13 2020-03-13 GPR52 Modulator compounds
BR112022018287A BR112022018287A2 (pt) 2020-03-13 2021-03-15 Compostos moduladores de gpr52
KR1020227035100A KR20220152296A (ko) 2020-03-13 2021-03-15 Gpr52 조절제 화합물
JP2022555137A JP7492597B2 (ja) 2020-03-13 2021-03-15 Gpr52モジュレーター化合物
SM20240402T SMT202400402T1 (it) 2020-03-13 2021-03-15 Composti modulatori gpr52
CA3175429A CA3175429A1 (en) 2020-03-13 2021-03-15 Gpr52 modulator compounds
LTEPPCT/GB2021/050638T LT4117784T (lt) 2020-03-13 2021-03-15 Gpr52 moduliuojantys junginiai
ES21713103T ES2992600T3 (en) 2020-03-13 2021-03-15 Gpr52 modulator compounds
HUE21713103A HUE068758T2 (hu) 2020-03-13 2021-03-15 GPR52 modulátorvegyületek
PL21713103.6T PL4117784T3 (pl) 2020-03-13 2021-03-15 Związki stanowiące modulator gpr52
CN202180033813.9A CN115515681B (zh) 2020-03-13 2021-03-15 Gpr52调节剂化合物
HRP20241375TT HRP20241375T1 (hr) 2020-03-13 2021-03-15 Spojevi modulatora gpr52
AU2021235257A AU2021235257B2 (en) 2020-03-13 2021-03-15 GPR52 modulator compounds
MX2022011333A MX2022011333A (es) 2020-03-13 2021-03-15 Compuestos moduladores de gpr52.
IL296413A IL296413B2 (en) 2020-03-13 2021-03-15 GPR52 modulator compounds
FIEP21713103.6T FI4117784T3 (fi) 2020-03-13 2021-03-15 GPR52:n modulaattoriyhdisteitä
US17/909,792 US12655120B2 (en) 2020-03-13 2021-03-15 GPR52 modulator compounds
DK21713103.6T DK4117784T3 (da) 2020-03-13 2021-03-15 Gpr52-modulatorforbindelser
RS20241089A RS66063B1 (sr) 2020-03-13 2021-03-15 Jedinjenja gpr52 modulatora
SI202130212T SI4117784T1 (sl) 2020-03-13 2021-03-15 Gpr52 modulatorne spojine
PCT/GB2021/050638 WO2021181122A1 (en) 2020-03-13 2021-03-15 Gpr52 modulator compounds
EP21713103.6A EP4117784B1 (en) 2020-03-13 2021-03-15 Gpr52 modulator compounds
PT217131036T PT4117784T (pt) 2020-03-13 2021-03-15 Compostos moduladores de gpr52

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2003668.7A GB202003668D0 (en) 2020-03-13 2020-03-13 GPR52 Modulator compounds

Publications (1)

Publication Number Publication Date
GB202003668D0 true GB202003668D0 (en) 2020-04-29

Family

ID=70453676

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2003668.7A Ceased GB202003668D0 (en) 2020-03-13 2020-03-13 GPR52 Modulator compounds

Country Status (23)

Country Link
US (1) US12655120B2 (enExample)
EP (1) EP4117784B1 (enExample)
JP (1) JP7492597B2 (enExample)
KR (1) KR20220152296A (enExample)
CN (1) CN115515681B (enExample)
AU (1) AU2021235257B2 (enExample)
BR (1) BR112022018287A2 (enExample)
CA (1) CA3175429A1 (enExample)
DK (1) DK4117784T3 (enExample)
ES (1) ES2992600T3 (enExample)
FI (1) FI4117784T3 (enExample)
GB (1) GB202003668D0 (enExample)
HR (1) HRP20241375T1 (enExample)
HU (1) HUE068758T2 (enExample)
IL (1) IL296413B2 (enExample)
LT (1) LT4117784T (enExample)
MX (1) MX2022011333A (enExample)
PL (1) PL4117784T3 (enExample)
PT (1) PT4117784T (enExample)
RS (1) RS66063B1 (enExample)
SI (1) SI4117784T1 (enExample)
SM (1) SMT202400402T1 (enExample)
WO (1) WO2021181122A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202003668D0 (en) 2020-03-13 2020-04-29 Heptares Therapeutics Ltd GPR52 Modulator compounds
EP4139284A1 (en) 2020-04-22 2023-03-01 Neurocrine Biosciences, Inc. Gpr52 modulators and methods of use
EP4330232A1 (en) * 2021-04-26 2024-03-06 Neurocrine Biosciences, Inc. Gpr52 modulators and methods of use
GB202113186D0 (en) 2021-09-15 2021-10-27 Heptares Therapeutics Ltd GPR52 Modulator compounds
WO2024091541A1 (en) * 2022-10-26 2024-05-02 Neurocrine Biosciences, Inc. Compounds and compositions as gpr52 modulators
WO2024091542A1 (en) * 2022-10-26 2024-05-02 Neurocrine Biosciences, Inc. Compounds and compositions as gpr52 modulators
AR130864A1 (es) * 2022-10-26 2025-01-29 Neurocrine Biosciences Inc Compuestos y composiciones como moduladores de gpr52
WO2025252061A1 (zh) * 2024-06-04 2025-12-11 海思科医药集团股份有限公司 一种gpr52激动剂及其在医药上的应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2327185A1 (en) 1998-04-08 1999-10-14 Abbott Laboratories Pyrazole inhibitors of cytokine production
US20010044445A1 (en) 1999-04-08 2001-11-22 Bamaung Nwe Y. Azole inhibitors of cytokine production
NZ526624A (en) 2000-12-22 2005-07-29 Ortho Mcneil Pharm Inc Substituted triazole diamine derivatives as kinase inhibitors
US20040220170A1 (en) 2003-05-01 2004-11-04 Atkinson Robert N. Pyrazole-amides and sulfonamides as sodium channel modulators
WO2005037797A1 (en) * 2003-10-21 2005-04-28 Pharmacia Corporation Substituted pyrazole urea compounds for the treatment of inflammation
JPWO2009107391A1 (ja) 2008-02-27 2011-06-30 武田薬品工業株式会社 6員芳香環含有化合物
KR20100097077A (ko) 2009-02-25 2010-09-02 주식회사 중외제약 Hsp90에 대한 억제 효능을 갖는 피리디논 유도체
EP2518054A1 (en) 2009-12-24 2012-10-31 Takeda Pharmaceutical Company Limited Amide compound
EP2530078A1 (en) 2010-01-27 2012-12-05 Takeda Pharmaceutical Company Limited Thiazole derivative
GB201317363D0 (en) 2013-10-01 2013-11-13 Eisai Ltd Novel compounds
MX373876B (es) * 2015-04-29 2020-03-26 Arena Pharm Inc 1-heteroaril-indolin-4-carboxamidas como moduladores de gpr52 útiles para el tratamiento o prevención de trastornos relacionados a las mismas.
WO2017077280A1 (en) 2015-11-02 2017-05-11 Sonia Lain Tetrahydroindazoles and medical uses thereof
US11279703B2 (en) 2016-12-01 2022-03-22 Aptose Biosciences Inc. Fused pyrimidine compounds as BRD4 and JAK2 dual inhibitors and methods for use thereof
CN111094278B (zh) 2017-09-13 2023-07-14 诺华股份有限公司 二苯基衍生物及其用途
JP7425724B2 (ja) 2017-10-17 2024-01-31 エピザイム,インコーポレイティド Ehmt2阻害剤としてのアミン置換複素環化合物及びその誘導体
AU2018353150B2 (en) 2017-10-18 2024-06-06 Epizyme, Inc. Methods of using EHMT2 inhibitors in treating or preventing blood disorders
US20210213014A1 (en) 2017-10-18 2021-07-15 Epizyme, Inc. Methods of using ehmt2 inhibitors in immunotherapies
CN114650992A (zh) 2019-11-08 2022-06-21 赫普泰雅治疗有限公司 Gpr52调节剂化合物
GB202003668D0 (en) 2020-03-13 2020-04-29 Heptares Therapeutics Ltd GPR52 Modulator compounds
GB202013558D0 (en) 2020-08-28 2020-10-14 Heptares Therapeutics Ltd GRP52 Modularor compounds

Also Published As

Publication number Publication date
IL296413B1 (en) 2025-11-01
KR20220152296A (ko) 2022-11-15
HUE068758T2 (hu) 2025-01-28
IL296413A (en) 2022-11-01
HRP20241375T1 (hr) 2024-12-20
FI4117784T3 (fi) 2024-10-10
PL4117784T3 (pl) 2025-01-13
JP2023519666A (ja) 2023-05-12
IL296413B2 (en) 2026-03-01
SMT202400402T1 (it) 2024-11-15
WO2021181122A1 (en) 2021-09-16
DK4117784T3 (da) 2024-10-14
BR112022018287A2 (pt) 2022-11-22
MX2022011333A (es) 2022-12-08
JP7492597B2 (ja) 2024-05-29
CA3175429A1 (en) 2021-09-16
US12655120B2 (en) 2026-06-16
AU2021235257A1 (en) 2022-10-06
CN115515681A (zh) 2022-12-23
PT4117784T (pt) 2024-10-07
LT4117784T (lt) 2024-10-25
EP4117784B1 (en) 2024-08-28
AU2021235257B2 (en) 2026-07-16
ES2992600T3 (en) 2024-12-16
SI4117784T1 (sl) 2025-03-31
RS66063B1 (sr) 2024-11-29
US20240254101A1 (en) 2024-08-01
EP4117784A1 (en) 2023-01-18
CN115515681B (zh) 2024-09-03

Similar Documents

Publication Publication Date Title
IL296413B2 (en) GPR52 modulator compounds
EP4452937A4 (en) CONNECTIONS
IL301007B1 (en) Gpr52 modulator compounds
GB202108818D0 (en) Compounds
SI4401833T1 (sl) Gpr52-modulatorne spojine
GB202001564D0 (en) Compounds
IL307230A (en) Pyrazolopyrimidine compounds
GB202113117D0 (en) Compounds
GB202011812D0 (en) Compounds
GB202011811D0 (en) Compounds
GB201918992D0 (en) GPR52 modulator compounds
GB201918974D0 (en) Gpr52 modulator compounds
GB201916298D0 (en) GPR52 modulator compounds
HK40073308A (en) Gpr52 modulator compounds
HK40093361A (en) Gpr52 modulator compounds
FI4441052T3 (fi) Yhdisteitä
GB202107637D0 (en) Compounds
GB202103482D0 (en) Compounds
GB202018411D0 (en) Malt-1 modulators i
GB202018034D0 (en) Compounds
GB202011924D0 (en) Compounds
GB202011537D0 (en) Compounds
GB202010862D0 (en) Compounds
GB202010359D0 (en) Compounds
GB202009944D0 (en) Compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)